FLSM
BLUE

Frazier Life Sciences Management’s bluebird bio BLUE Stock Holding History

Frazier Life Sciences Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-85,495
Closed -$2.19M – 52
2024
Q1 		$2.19M Hold
85,495
– – 0.09% 49
2023
Q4 		$2.36M Hold
85,495
– – 0.13% 46
2023
Q3 		$5.2M Hold
85,495
– – 0.35% 43
2023
Q2 		$5.63M Buy
85,495
+13,457
+19% +$984K 0.34% 40
2023
Q1 		$4.58M Hold
72,038
– – 0.33% 43
2022
Q4 		$9.97M Hold
72,038
– – 0.62% 32
2022
Q3 		$9.12M Buy
+72,038
New +$8.15M 0.7% 31

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Frazier Life Sciences Management's BLUE Position: Q2 2024 in Review

Frazier Life Sciences Management sold out of bluebird bio (BLUE) in Q2 2024, closing a stake of 85,495 shares — an estimated $2.19M sold.

Frazier Life Sciences Management first reported a position in BLUE in Q3 2022 and held it in 7 quarters. The position peaked at $9.97M in Q4 2022. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2024.

  • Frazier Life Sciences Management reported no remaining bluebird bio position as of Q2 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 85,495 bluebird bio shares in Q2 2024, an estimated $2.19M.
  • Frazier Life Sciences Management first reported a position in bluebird bio in Q3 2022 and held it in 7 quarters.
  • Frazier Life Sciences Management's bluebird bio position peaked at $9.97M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2024.

Based on Frazier Life Sciences Management's 13F filing for Q2 2024, filed 15 Aug 2024.